Efg Asset Management (North America) Corp. Vaxcyte, Inc. Transaction History
Efg Asset Management (North America) Corp.
- $585 Million
- Q3 2024
A detailed history of Efg Asset Management (North America) Corp. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 22,818 shares of PCVX stock, worth $2.09 Million. This represents 0.45% of its overall portfolio holdings.
Number of Shares
22,818
Previous 30,442
25.04%
Holding current value
$2.09 Million
Previous $2.3 Million
13.36%
% of portfolio
0.45%
Previous 0.41%
Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
354Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$1.05 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$1 Billion0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$910 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$796 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$449 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.43B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...